Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98

Repligen Co. (NASDAQ:RGEN) gapped down before the market opened on Thursday . The stock had previously closed at $160.98, but opened at $154.59. Repligen shares last traded at $156.00, with a volume of 183,643 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RGEN. Stifel Nicolaus upped their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. KeyCorp upped their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Stock Performance

The stock’s 50-day moving average is $189.09 and its 200-day moving average is $173.09. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 218.25, a P/E/G ratio of 5.14 and a beta of 1.02. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The company had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. During the same quarter last year, the company earned $0.68 earnings per share. Repligen’s revenue for the quarter was down 16.6% on a year-over-year basis. On average, analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now directly owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock valued at $5,039,532 over the last 90 days. 1.20% of the stock is owned by corporate insiders.

Institutional Trading of Repligen

Hedge funds have recently made changes to their positions in the stock. Fortis Capital Advisors LLC acquired a new stake in shares of Repligen during the fourth quarter worth approximately $35,000. Benjamin F. Edwards & Company Inc. grew its position in shares of Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares in the last quarter. Park Place Capital Corp grew its position in shares of Repligen by 90.2% during the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after buying an additional 120 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Repligen during the fourth quarter worth approximately $48,000. Finally, Signaturefd LLC boosted its holdings in Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.